...
首页> 外文期刊>European Journal of Radiology >A meta-analysis of 18FDG-PET-CT, 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer
【24h】

A meta-analysis of 18FDG-PET-CT, 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer

机译:18FDG-PET-CT,18FDG-PET,MRI和骨闪烁显像的荟萃分析对肺癌患者骨转移的诊断

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background and purpose: Lung cancer is the most common cause of cancer related death among both men and women worldwide. The skeleton is the most common site of cancer metastasis. Early detection is crucial for prognosis. To evaluate and compare the capability for bone metastasis assessment of [ 18F] fluoro-2-d-glucose positron emission tomography with computed tomography ( 18FDG-PET-CT), [ 18F] fluoro-2-d-glucose positron emission tomography ( 18FDG-PET), magnetic resonance imaging (MRI) and bone scintigraphy (BS) in lung cancer patients, a meta-analysis is preformed. Methods: We searched MEDLINE, OVID, EMBASE and the Cochrane Library for studies evaluating diagnosis validity of 18FDG-PET-CT, 18FDG-PET, MRI and BS between January 1990 and August 2010. Meta-analysis methods were used to pool sensitivity, specificity, diagnostic odd ratios (DORs) and to construct a summary receiver-operating characteristic curve (SROC). Results: A total of 17 articles (9 18FDG-PET-CT studies, 9 18FDG-PET studies, 6 MRI studies and 16 BS studies) that included 2940 patients who fulfilled all of the inclusion criteria were considered for inclusion in the analysis. The pooled sensitivity for the detection of bone metastasis in lung cancer using 18FDG-PET-CT, 18FDG-PET, MRI and BS were 0.92 (95% CI, 0.88-0.95), 0.87 (95% CI, 0.81-0.92), 0.77 (95% CI, 0.65-0.87) and 0.86 (95% CI, 0.82-0.89), respectively. The pooled specificity for the detection of bone metastasis from lung cancer using 18FDG-PET-CT, 18FDG-PET, MRI and BS were 0.98 (95% CI, 0.97-0.98), 0.94 (95% CI, 0.92-0.96), 0.92 (95% CI, 0.88-0.95), 0.88 (95% CI, 0.86-0.89), respectively. The pooled DORs estimates for 18FDG- PET-CT 449.17 were significantly higher than for 18FDG-PET (118.25, P 0.001), MRI (38.27, P 0.001) and BS (63.37, P 0.001). The pooled sensitivity of BS was not correlated with the prevalence of bone metastasis. Conclusion: The results showed that both 18FDG-PET-CT and 18FDG-PET were better imaging methods for diagnosing bone metastasis from lung cancer than MRI and BS. 18FDG-PET-CT has higher diagnostic value (sensitivity, specificity and DORs) for diagnosing bone metastasis from lung cancer than any other imaging methods.
机译:背景与目的:肺癌是全世界男女癌症相关死亡的最常见原因。骨骼是癌症转移的最常见部位。早期发现对于预后至关重要。要评估和比较[18F]氟-2-d-葡萄糖正电子发射断层扫描与计算机断层扫描(18FDG-PET-CT),[18F]氟-2-d-葡萄糖正电子发射断层扫描(18FDG)的骨转移评估能力-PET),磁共振成像(MRI)和骨闪烁显像(BS)对肺癌患者进行了荟萃分析。方法:我们在MEDLINE,OVID,EMBASE和Cochrane库中进行了研究,以评估18FDG-PET-CT,18FDG-PET,MRI和BS在1990年1月至2010年8月之间的诊断有效性。采用荟萃分析方法汇总敏感性,特异性,诊断奇数比(DOR)并构建汇总的接收器工作特性曲线(SROC)。结果:共纳入17篇文章(9篇18FDG-PET-CT研究,9篇18FDG-PET研究,6篇MRI研究和16篇BS研究),其中包括2940例符合所有纳入标准的患者。使用18FDG-PET-CT,18FDG-PET,MRI和BS进行肺癌骨转移检测的合并敏感性分别为0.92(95%CI,0.88-0.95),0.87(95%CI,0.81-0.92),0.77 (95%CI,0.82-0.89)(95%CI,0.65-0.87)和0.86(95%CI,0.82-0.89)。使用18FDG-PET-CT,18FDG-PET,MRI和BS检测肺癌骨转移的总特异性分别为0.98(95%CI,0.97-0.98),0.94(95%CI,0.92-0.96),0.92 (95%CI,0.88-0.95),0.88(95%CI,0.86-0.89)。 18FDG-PET-CT 449.17的汇总DOR估计值显着高于18FDG-PET(118.25,P <0.001),MRI(38.27,P <0.001)和BS(63.37,P <0.001)。 BS的合并敏感性与骨转移的发生率无关。结论:结果表明,18FDG-PET-CT和18FDG-PET都是比MRI和BS更好的诊断肺癌骨转移的影像学方法。 18FDG-PET-CT在诊断肺癌骨转移方面具有比其他任何成像方法更高的诊断价值(敏感性,特异性和DOR)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号